First preclinical proof-of-concept of mutation-based individualized cancer vaccine

Deep sequencing of immunogenic mutations may pave way for customized immunotherapy

Mainz, January 17, 2012 – The Institute of Translational Oncology (TRON) together with BioNTech AG today announced the publication of a joint paper in the international journal Cancer Research that describes a new path for individually tailored cancer therapy. An interdisciplinary team of genome scientists and immunologists led by the cancer researcher Prof. Ugur Sahin for the first time demonstrated that whole cancer genome information could be used to tailor effective cancer specific vaccines.

Read more (DOI; PubMed)

Cancer Research